Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Docetaxel - Sanofi Aventis

Next Previous
Drug Profile

Docetaxel - Sanofi Aventis

Alternative Names: Docetaxol; NSC 628503; RP 56976; Taxotere; XPR 6976; XRP-6976

Latest Information Update: 09 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Bristol-Myers Squibb; National Cancer Institute (USA); Radiation Therapy Oncology Group; Roche; Sanofi; University of Iowa; University of Texas M. D. Anderson Cancer Center; West German Study Group
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer
  • Registered Solid tumours
  • No development reported Sarcoma
  • Discontinued Fallopian tube cancer; Pancreatic cancer; Peritoneal cancer

Most Recent Events

  • 09 Jan 2026 No development reported - Phase-III for Prostate cancer (Combination therapy, Second-line therapy or greater) in USA (IV)
  • 08 Jan 2026 No development reported - Phase-III for Breast cancer (Combination therapy, Late-stage disease, Neoadjuvant therapy) in Australia (IV)
  • 08 Jan 2026 No development reported - Phase-III for Prostate cancer (Combination therapy, Second-line therapy or greater) in Canada (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top